ArticleJournal of experimental & clinical cancer research : CR2013
SOX7 is down-regulated in lung cancer.
Article in Journal of experimental & clinical cancer research : CR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 71 citations in OpenAlex.
- Comprehensive Analyses of SOX7 Provide Novel Insights on Its Tumor Suppressor Role and Its Target Genes with Therapeutic Implications in Multiple Myeloma.International journal of molecular sciences · 2026Article
- SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma.Cell death discovery · 2026Article
- Role of the SOX family in non‑small cell lung cancer: Molecular mechanisms and therapeutic implications (Review).Oncology reports · 2026Review
- Non-small cell lung cancer map and analysis: exploring interconnected oncogenic signal integrators.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Genetic and Epigenetic Aberrations ofCurrent issues in molecular biology · 2025Article
- SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.Molecular biomedicine · 2024Article
- Alveolar type 2 cells marker geneFrontiers in oncology · 2024Article
- Targeting SOX18 Transcription Factor Activity by Small-Molecule Inhibitor Sm4 in Non-Small Lung Cancer Cell Lines.International journal of molecular sciences · 2023Article
- Bioinformatics analysis of SOXF family genes reveals potential regulatory mechanism and diagnostic value in cancers.Annals of translational medicine · 2022Article
- Exploring the mechanism of aidi injection for lung cancer by network pharmacology approach and molecular docking validation.Bioscience reports · 2021Article
- Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer.BMC cancer · 2020Article
- Review
- An overview of the potential anticancer properties of cardamonin.Exploration of targeted anti-tumor therapy · 2020Review
- A brief overview of antitumoral actions of bruceine D.Exploration of targeted anti-tumor therapy · 2020Review
- Long noncoding RNA HAND2-AS1 restrains proliferation and metastasis of breast cancer cells through sponging miR-1275 and promoting SOX7.Cancer biomarkers : section A of Disease markers · 2020Article
- Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review.Frontiers in pharmacology · 2019Review
- SOX7 Target Genes and Their Contribution to Its Tumor Suppressive Function.International journal of molecular sciences · 2018Article
- GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines.PloS one · 2018Article
- MicroRNA-29a Functions as a Tumor Suppressor and Increases Cisplatin Sensitivity by Targeting NRAS in Lung Cancer.Technology in cancer research & treatment · 2018Article
- The component formula ofOncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSOX7 is a transcription factor belonging to the SOX family. Its role in lung cancer is unknown.
methodsIn this study, whole genomic copy number analysis was performed on a series of non-small cell lung cancer (NSCLC) cell lines and samples from individuals with epidermal growth factor receptor (EGFR) mutations using a SNP-Chip platform. SOX7 was measured in NSCLC samples and cell lines, and forced expressed in one of these lines.
resultsA notable surprise was that the numerous copy number (CN) changes observed in samples of Asian, non-smoking EGFR mutant NSCLC were nearly the same as those CN alterations seen in a large collection of NSCLC from The Cancer Genome Atlas which is presumably composed of predominantly Caucasians who often smoked. However, four regions had CN changes fairly unique to the Asian EGFR mutant group. We also examined CN changes in NSCLC lines. The SOX7 gene was homozygously deleted in one (HCC2935) of 10 NSCLC cell lines and heterozygously deleted in two other NSCLC lines. Expression of SOX7 was significantly downregulated in NSCLC cell lines (8/10, 80%) and a large collection of NSCLC samples compared to matched normal lung (57/62, 92%, p= 0.0006). Forced-expression of SOX7 in NSCLC cell lines markedly reduced their cell growth and enhanced their apoptosis.
conclusionThese data suggest that SOX7 is a novel tumor suppressor gene silenced in the majority of NSCLC samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.